Trial Profile

A Phase II Study of Neoadjuvant Chemoradiation Plus PD-1 Antibody(SHR-1210) in the Locally Advanced Proximal Stomach Adenocarcinoma (Neo-PLANET)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 04 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Camrelizumab (Primary) ; Capecitabine (Primary) ; Oxaliplatin (Primary)
Indications Adenocarcinoma; Gastric cancer
Focus Therapeutic Use
Acronyms Neo-PLANET

Most Recent Events

21 Sep 2021 Results assessing the efficacy and safety of camrelizumab plus chemoradiation as neoadjuvant therapy for locally advanced proximal gastric cancer, presented at the 46th European Society for Medical Oncology Congress.
21 Sep 2020 Interim results (N=15), presented at the 45th European Society for Medical Oncology Congress
24 Aug 2020 Planned End Date changed from 1 Oct 2020 to 1 Dec 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com